Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05896904

Enrollment

100

Registered

2023-06-09

Start date

2022-09-09

Completion date

2023-08-31

Last updated

2023-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure, Transthyretin Amyloid Cardiomyopathy

Keywords

Heart Failure, Echocardiography

Brief summary

Clinical comparison of patients with transthyretin cardiac amyloidosis and patients with heart failure with reduced ejection fraction

Interventions

DIAGNOSTIC_TESTEchocardiography

Echocardiography

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

SCREENING

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

65 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age \>65 * ATTRwt diagnosis for patients, either with DPD-scintigraphy or myocardiac biopsy * informed consent

Exclusion criteria

* Alder \<65 * No ATTRwt diagnosis

Design outcomes

Primary

Measure	Time frame	Description
intraventricular wall thickness	1 year	echocardiographic measurement

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026